** Shares of Australia's LTR Pharma LTP.AX rise as much as 25.9% to A$0.535, their biggest gain since June 5

** The clinical-stage biopharma firm executed a binding term sheet with U.S.-based pharmacy operator Strive Specialities

** The binding term sheet establishes exclusive U.S. pharmacy fulfillment rights for ROXUS, an intranasal treatment for erectile dysfunction

** Around 2.1 mln shares change hands, nearly 4x 30-day average

** LTP down 31.3% YTD